TrialClinical Study to Assess the Efficacy of Once-daily IMM-124E (Travelan®) in a Controlled Human Infection Model.
Trial details
- Registry ID
- NCT05933525
- Phase
- Phase 2
IMRN
Immuron Ltd.
Company identity checked against sources
Browse linked trials and recorded changes, or follow this company for updates.
1Trials in this database
3Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity source| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Clinical Study to Assess the Efficacy of Once-daily IMM-124E (Travelan®) in a Controlled Human Infection Model.NCT05933525 | IMRN | Phase 2 | Completed | 2024-07-01Actual |
Latest recorded trial changes
Clinical Study to Assess the Efficacy of Once-daily IMM-124E (Travelan®) in a Controlled Human Infection Model.
NCT05933525 · Immuron Ltd.
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Compare wording
− Before
Measure: To Measure the Protective Efficacy of Oral Administration of Travelan Compared to Placebo Against Moderate-to-severe Diarrhea Following With E.Coli (ETEC) Challenge.
+ After
Measure: Protective Efficacy of a Single Daily Dose of Travelan Against Moderate-to-severe Diarrhea Following Challenge With Enterotoxigenic E. Coli (ETEC) Strain H10407.
Clinical Study to Assess the Efficacy of Once-daily IMM-124E (Travelan®) in a Controlled Human Infection Model.
NCT05933525 · Immuron Ltd.
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Compare wording
− Before
Measure: To measure the protective efficacy of oral administration of Travelan compared to placebo against moderate-to-severe diarrhea following with E.coli (ETEC) challenge.
+ After
Measure: To Measure the Protective Efficacy of Oral Administration of Travelan Compared to Placebo Against Moderate-to-severe Diarrhea Following With E.Coli (ETEC) Challenge.
Actual enrollment increased by 3 participants
− Before
60 participants (actual)
+ After
63 participants (actual)